160 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
This Small Biotech Is Building on a Surprising Success https://www.fool.com/investing/2018/04/24/this-small-biotech-is-building-on-a-surprising-suc.aspx?source=iedfolrf0000001 Apr 24, 2018 - Enanta Pharmaceuticals helped AbbVie score big last year. Now it's setting its sights even higher.
Novo Nordisk Obtains Licence for Sickle Cell Disease Program http://www.zacks.com/stock/news/298364/novo-nordisk-obtains-licence-for-sickle-cell-disease-program?cid=CS-ZC-FT-298364 Apr 06, 2018 - Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Novo Nordisk A/S (NVO) Investor Presentation - Slideshow https://seekingalpha.com/article/4158935-novo-nordisk-s-nvo-investor-presentation-slideshow?source=feed_sector_healthcare Mar 26, 2018 - The following slide deck was published by Novo Nordisk A/S in conjunction with this event.
Novo Nordisk Poised on Strong Pipeline Amid Competition http://www.zacks.com/stock/news/296396/novo-nordisk-poised-on-strong-pipeline-amid-competition?cid=CS-ZC-FT-296396 Mar 21, 2018 - Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns http://www.zacks.com/stock/news/295726/diabetes-devices-market-on-a-tear-3-stocks-for-solid-returns?cid=CS-ZC-FT-295726 Mar 15, 2018 - Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code http://www.zacks.com/stock/news/295546/orexigen-plummets-on-filing-of-chapter-11-of-bankruptcy-code?cid=CS-ZC-FT-295546 Mar 14, 2018 - Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
M&A, Innovation & New Drugs to Drive Pharma Stocks http://www.zacks.com/commentary/152408/ma-innovation-new-drugs-to-drive-pharma-stocks?cid=CS-ZC--152408 Mar 08, 2018 - M&A, Innovation & New Drugs to Drive Pharma Stocks
Rule Breaker February Mailbag: Reflections on the Fool's Own ETF, Plus Some Un-Foolish Investing Woes https://www.fool.com/investing/2018/03/07/rule-breaker-february-mailbag-reflections-on-the-f.aspx?source=iedfolrf0000001 Mar 07, 2018 - Some listeners to the podcast are interested in the Fool 100 Index. Others have questions and stories that cut to the heart our investing philosophy.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio http://www.zacks.com/stock/news/294071/4-buy-ranked-large-cap-pharma-stocks-to-boost-your-portfolio?cid=CS-ZC-FT-294071 Feb 28, 2018 - Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP http://www.zacks.com/stock/news/293908/pfizer-gets-mixed-feedback-on-cancer-treatments-from-chmp?cid=CS-ZC-FT-293908 Feb 27, 2018 - CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.

Pages: 1234567891011...16

<<<Page 6>